Mark A. Goldberg, MD ’86

What does it take to be chief operating officer of a leading global biopharmaceutical services provider, with 8,800 employees and locations in 52 countries? And what drives this executive officer of an organization The Boston Globe ranks as a top-performing publicly held company and top employer in Massachusetts?

For Mark Goldberg, MD, COO of PAREXEL International, which has provided clinical development know-how for more than 25 years, it’s a passion for technology and medicine, manifested in a knack for erasing international borders to speed the development of therapeutics by expanding patient enrollment in clinical research. PAREXEL has supported thousands of clinical trials by accessing diverse patient populations to generate statistically robust data.

Goldberg, who received a degree in computer science and engineering from MIT and spent summers in the computer science lab at Mass General before UMMS, says that physicians are eager to link to global clinical trials to give their patients access to the most advanced therapies and care.

Goldberg chose UMMS because he found it “uniquely supportive, particularly of the opportunities I had to continue lab work at MGH” where he eventually trained in diagnostic radiology, served as chief resident and joined the staff. The result of an MD on top of an engineering degree, Goldberg said, “was a unique foundation to combine medicine and technology to support the development of new therapies.”

After involvement in a telehealth spin-off from MGH, Goldberg joined PAREXEL in 1997 to establish its Medical Imaging Group and then helped found its technology subsidiary, Perceptive Informatics, in 2000. In 2005, he took responsibility for the company’s Clinical Research Services business and has been able to combine his medical, technical and clinical expertise to provide evolving capabilities across a range of therapeutic areas and all phases of clinical research. He has also foreseen opportunities to help the industry move from paper-based, manual processes to greater use of technology.  His goal is to increase the productivity and efficiency of clinical research and more rapidly bring safe and effective treatments to patients worldwide.

Back to contents